Filing Flows › Xeris Biopharma Holdings (XERS) › Q2 2026
Xeris Biopharma Holdings (XERS) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 6, 2026
Xeris Biopharma Holdings (XERS) reported revenue of $92.1M for the second quarter 2026 (Q2 2026), +29% from a year earlier and +11% from the quarter before. Operating margin was 5.6%, net loss $31.1M (33.8% of revenue).
Xeris Biopharma Holdings, Q2 2026: revenue $92.1M (+29% year over year), operating margin 5.6%, net loss $31.1M, operating cash flow $8.3M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $92.1M | +11% | +29% |
| Operating profit | $5.2M | -35% | +15% |
| Net earnings | −$31.1M | -1492% | — |
| Operating cash flow | $8.3M | -16% | 45× |
What changed
Revenue was $92.1M in Q2 2026, up 29% year over year and up 11% from the previous quarter. Recorlev was the largest line at 62% of revenue. Recorlev added $25.3M year over year (up 81%), 123% of the total change. Royalty, contract and other revenue declined 71%.
Operating profit was $5.2M, a 5.6% margin (down 0.6 points year over year). Of the extra revenue versus Q2 2025, 3% reached operating profit, below the 6% margin then. Total costs grew 30% against revenue growth of 29%. The fastest-growing cost line was SG&A (+37%). The quarter ended with a net loss of $31.1M, after a profit of $2.2M the previous quarter. Net interest and other expense of $36.3M was the main reason.
Operating cash flow was $8.3M (up 4440% year over year). Non-cash charges added back $323K of depreciation and amortization and $11.1M of share-based compensation. Working capital and other items added $28.0M.
Questions
What was Xeris Biopharma Holdings' revenue in the second quarter 2026?
Xeris Biopharma Holdings (XERS) reported revenue of $92.1M for the second quarter 2026 (Q2 2026), +29% from a year earlier and +11% from the quarter before.
Was Xeris Biopharma Holdings profitable in the second quarter 2026?
Operating profit was $5.2M (5.6% of revenue) and net loss $31.1M.